{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:57:41Z","timestamp":1780775861069,"version":"3.54.1"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>International guidelines use cancer antigen (CA) 125 thresholds to recommend which patients with pelvic masses should undergo evaluation by gynecologic oncologists for ovarian cancer. However, CA-125 thresholds were developed from White populations. If CA-125 levels differ among patient populations, current guidelines may contribute to delayed ovarian cancer diagnoses among women of other races and ethnicities than White.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine CA-125 levels at ovarian cancer diagnosis by patient race and ethnicity and associations of elevated CA-125 levels with timely treatment.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study included all patients with ovarian cancer diagnosed between January 1, 2004, and December 31, 2020, using the US National Cancer Database. The data analysis was performed between November 1, 2023, and July 10, 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Patient race and ethnicity as identified in the National Cancer Database.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>Cancer antigen 125 level was defined as elevated or borderline and negative or normal. Multivariable logistic regression models were used to examine the association of patient race and ethnicity with CA-125 level overall and for epithelial and high-grade serous cancers. Generalized linear models were used to examine the association of CA-125 level with days from diagnosis to chemotherapy start for patients with stage II to IV ovarian cancer.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 250\u202f749 patients with ovarian cancer diagnosed between 2004 and 2020 (median [IQR] age, 62.0 [52.0-73.0] years; 0.4% American Indian, 3.7% Asian, 8.6% Black, 85.2% White, and 2.0% other or unknown race and 6.7% Hispanic, 88.8% non-Hispanic, and 4.6% of unknown ethnicity), 212\u202f477 had measured CA-125 levels, and 88.2% had an elevated CA-125 level at diagnosis. Patients with American Indian, Asian, or Black race were less likely to have an elevated CA-125 level at ovarian cancer diagnosis than White patients. In multivariable analyses adjusted for stage, comorbidities, and menopausal status, Black patients had lower odds of elevated CA-125 levels (adjusted odds ratio [AOR], 0.77; 95% CI, 0.74-0.81) compared with White patients, as did American Indian patients (AOR, 0.77; 95% CI, 0.62-0.94). Among patients with high-grade serous ovarian cancer only, Black patients had a lower odds of having an elevated CA-125 level at diagnosis (AOR, 0.81; 95% CI, 0.73-0.91). Patients with stage II to IV ovarian cancer with false-negative CA-125 findings at diagnosis had 9.38 days longer (95% CI, 8.43-10.34 days) to chemotherapy start compared with patients with an elevated CA-125 level.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of patients with ovarian cancer, American Indian and Black patients were 23% less likely to have an elevated CA-125 level at diagnosis. Current CA-125 thresholds may miss racially and ethnically diverse patients with ovarian cancer. Work is needed to develop inclusive CA-125 thresholds and diagnostic guidelines and not compound disparities in ovarian cancer diagnosis and treatment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.1292","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T20:56:31Z","timestamp":1742504191000},"page":"e251292","source":"Crossref","is-referenced-by-count":14,"title":["Cancer Antigen 125 Levels at Time of Ovarian Cancer Diagnosis by Race and Ethnicity"],"prefix":"10.1001","volume":"8","author":[{"given":"Anna Jo Bodurtha","family":"Smith","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania Health Systems, Philadelphia"},{"name":"Department of Obstetrics and Gynecology, University of Pennsylvania Health Systems, Philadelphia"},{"name":"Leonard Davis Institute of Health Economics, University of Pennsylvania Health Systems, Philadelphia"},{"name":"Penn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania Health Systems, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gleason","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Pennsylvania Health Systems, Philadelphia"},{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Kadiyala","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Howell","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Pennsylvania Health Systems, Philadelphia"},{"name":"Leonard Davis Institute of Health Economics, University of Pennsylvania Health Systems, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Penn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania Health Systems, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"12","key":"zoi250092r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12123730","article-title":"CA125 and ovarian cancer: a comprehensive review.","volume":"12","author":"Charkhchi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"zoi250092r2","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma.","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"issue":"1","key":"zoi250092r3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0039-6109(16)41440-4","article-title":"Intensive surgical and chemotherapeutic management of advanced ovarian cancer.","volume":"58","author":"Griffiths","year":"1978","journal-title":"Surg Clin North Am"},{"issue":"1","key":"zoi250092r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi250092r5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer.","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi250092r7","first-page":"1320","article-title":"ACOG releases guidelines on management of adnexal masses.","volume":"77","author":"Graham","year":"2008","journal-title":"Am Fam Physician"},{"issue":"5","key":"zoi250092r8","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1097\/AOG.0000000000001768","article-title":"Practice bulletin No. 174: evaluation and management of adnexal masses.","volume":"128","author":"Eskander","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"1","key":"zoi250092r9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/hex.13681","article-title":"Women\u2019s experiences along the ovarian cancer diagnostic pathway in Catalonia: a qualitative study.","volume":"26","author":"Vela-Vallesp\u00edn","year":"2023","journal-title":"Health Expect"},{"issue":"1","key":"zoi250092r10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1089\/whr.2020.0090","article-title":"Patient and provider perspectives on barriers to accessing gynecologic oncologists for ovarian cancer surgical care.","volume":"1","author":"Weeks","year":"2020","journal-title":"Womens Health Rep (New Rochelle)"},{"issue":"4","key":"zoi250092r11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2354.2005.00596.x","article-title":"Barriers to effective communication across the primary\/secondary interface: examples from the ovarian cancer patient journey (a qualitative study).","volume":"14","author":"Farquhar","year":"2005","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"15","key":"zoi250092r13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250092r15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ygyno.2021.01.011","article-title":"Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).","volume":"161","author":"Cramer","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"1","key":"zoi250092r16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13048-019-0591-4","article-title":"Development and validation of circulating CA125 prediction models in postmenopausal women.","volume":"12","author":"Sasamoto","year":"2019","journal-title":"J Ovarian Res"},{"issue":"5","key":"zoi250092r17","first-page":"489","article-title":"Factors influencing serum CA125II levels in healthy postmenopausal women.","volume":"10","author":"Pauler","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"zoi250092r18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ygyno.2008.05.006","article-title":"The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.","volume":"110","author":"Johnson","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"6","key":"zoi250092r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.18602","article-title":"Uptake and outcomes of neoadjuvant chemotherapy among US patients with less common epithelial ovarian carcinomas.","volume":"6","author":"Matsuo","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi250092r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.39593","article-title":"Neighborhood and individual socioeconomic disadvantage and survival among patients with nonmetastatic common cancers.","volume":"4","author":"Cheng","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi250092r26","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1158\/1055-9965.EPI-18-1120","article-title":"Predicting circulating CA125 levels among healthy premenopausal women.","volume":"28","author":"Sasamoto","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"zoi250092r27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(23)00335-2","article-title":"Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial.","volume":"24","author":"Menon","year":"2023","journal-title":"Lancet Oncol"},{"issue":"13","key":"zoi250092r28","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study.","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi250092r29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/aje\/kww086","article-title":"Estimating the prevalence of ovarian cancer symptoms in women aged 50 years or older: problems and possibilities.","volume":"184","author":"Sun","year":"2016","journal-title":"Am J Epidemiol"},{"key":"zoi250092r30","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8107906","article-title":"Neutrophil-to-lymphocyte ratio in ovarian cancer patients with low CA125 concentration.","volume":"2019","author":"Zhang","year":"2019","journal-title":"Biomed Res Int"},{"issue":"1","key":"zoi250092r31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13048-023-01207-0","article-title":"MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer.","volume":"16","author":"Wu","year":"2023","journal-title":"J Ovarian Res"},{"issue":"6","key":"zoi250092r32","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1159\/000475911","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in ovarian cancer: a systematic review and meta-analysis of observational studies.","volume":"41","author":"Huang","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"zoi250092r33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ygyno.2014.01.026","article-title":"Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.","volume":"132","author":"Williams","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"5","key":"zoi250092r34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12094-015-1387-7","article-title":"Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion.","volume":"18","author":"Polat","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"zoi250092r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.06.003","article-title":"Benign ethnic neutropenia.","volume":"37","author":"Atallah-Yunes","year":"2019","journal-title":"Blood Rev"},{"issue":"19","key":"zoi250092r36","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1002\/cncr.33620","article-title":"Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.","volume":"127","author":"Lynce","year":"2021","journal-title":"Cancer"},{"key":"zoi250092r37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ygyno.2024.09.018","article-title":"Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.","volume":"191","author":"Caruso","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"12","key":"zoi250092r38","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for outcomes research: a review.","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"key":"zoi250092r12","author":"Kadiyala"},{"key":"zoi250092r6","unstructured":"Ovarian cancer: recognition and initial management. National Institute for Health and Care Excellence. Published April 11, 2011. Updated October 2, 2023. Accessed April 17, 2024. https:\/\/www.nice.org.uk\/guidance\/cg122"},{"key":"zoi250092r14","unstructured":"Race of the population of the United States, by states: 1970. US Census Bureau; 1970. Accessed April 17, 2024. https:\/\/www2.census.gov\/library\/publications\/decennial\/1970\/pc-s1-supplementary-reports\/pc-s1-11.pdf"},{"key":"zoi250092r19","unstructured":"NAACCR item #3818: CA-125 pretreatment interpretation. National Cancer Institute SEER Registrar Staging Assistant. Accessed January 24, 2024. https:\/\/staging.seer.cancer.gov\/naaccr\/item\/eod_public\/3.0\/3818\/?breadcrumbs"},{"key":"zoi250092r20","unstructured":"NCCN clinical practice guidelines in oncology. National Comprehensive Cancer Network; 2024. Accessed July 10, 2024. https:\/\/www.nccn.org\/patients"},{"key":"zoi250092r22","unstructured":"ICD-0-3 SEER site\/histology validation list. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Published April 29, 2022. Accessed April 17, 2024. https:\/\/seer.cancer.gov\/icd-o-3\/sitetype.icdo3.20220429.pdf"},{"key":"zoi250092r24","unstructured":"Reid? F, Bajwa? A. The World Ovarian Cancer Coalition atlas 2023 global trends in incidence, mortality, and survival. World Ovarian Cancer Coalition; 2023. Accessed April 17, 2024. https:\/\/worldovariancancercoalition.org\/wp-content\/uploads\/2023\/04\/World-Ovarian-Cancer-Coalition-Atlas-2023-FINAL.pdf"},{"key":"zoi250092r25","unstructured":"Ovarian cancer statistics. Centers for Disease Control and Prevention. Accessed April 17, 2024. https:\/\/www.cdc.gov\/ovarian-cancer\/statistics\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/cancer\/ovarian\/statistics\/index.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2831745\/smith_2025_oi_250092_1741884754.4366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T20:56:35Z","timestamp":1742504195000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2831745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.1292","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}